Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company is headquartered in Worthing, West Sussex and currently employs 602 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Follow-Up Questions
Allergy Therapeutics PLC 'in CEO'su kimdir?
Mr. Manuel Llobet 2009 'den beri şirketle birlikte olan Allergy Therapeutics PLC 'in Chief Executive Officer 'ıdır.
AGYTF hissesinin fiyat performansı nasıl?
AGYTF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Allergy Therapeutics PLC için ana iş temaları veya sektörler nelerdir?
Allergy Therapeutics PLC Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Allergy Therapeutics PLC için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 5 al, 2 tut, 0 sat ve 3 güçlü sat içermektedir
